Safety And Efficacy Of Vaginal Misoprostol In Treatment Of First Trimester Miscarriage

Mohamed S. A. Emarah (MD)
Department of Obstetrics and Gynaecology,
Benha Teaching Hospital, Egypt.

ABSTRACT
Objective: This study was conducted to determine the outcome of medical treatment with vaginal misoprostol in missed miscarriage. Methods: A randomized controlled study was performed in Benha Teaching Hospital between April 2016 and June 2017. Eighty patients diagnosed with miscarriage before 13 weeks of gestation and wanted to try medical treatment were included. A detailed ultrasound scan was performed to confirm the diagnosis. Patients took 400 microgram (mcg) of misoprostol vaginal as an initial dose, and repeated the same dose 4-6 hours apart. Successful medical abortion was defined as spontaneous expulsion of gestational products (including gestational sac, embryo, fetus, and placenta). Ultrasonography at least 24 hours later from the initial dose to assess the uterine cavity if gestational products were not expelled, surgical evacuation was performed. Results: About two-thirds of patients (77.5%) had a successful outcome. The median interval time from pill to expulsion was 18 hours in the successful medical treatment group. Conclusion: Medical treatment with vaginal misoprostol should be a proper option for the first trimester miscarriage, especially for the patient who want to avoid surgical procedure. We can reduce the unnecessary sedation or surgical intervention in the patients with the first trimester miscarriage.

INTRODUCTION
Miscarriage, also known as missed abortion, is generally defined as spontaneous loss of a pre-viable pregnancy\(^{(1)}\). It complicates 15% to 20% of all pregnancies, 75% of miscarriages occur during the first trimester\(^{(2-4)}\). So long as ectopic pregnancy is ruled out, almost half of miscarriage get to be expelled spontaneously within two to six weeks\(^{(5,6)}\). However, anxiety of the women diagnosed with miscarriage and symptoms such as vaginal bleeding and abdominal pain usually require prompt interventions for termination of miscarriage\(^{(7)}\).

Surgical evacuation using vacuum aspiration or curettage is the most common method for termination of miscarriages\(^{(6)}\). It is widely used because it can achieve complete removal of products of conception in a short time. A kind of anesthesia or sedation is usually necessary during surgical evacuation. However, there are some patients who want to avoid any surgical intervention and prefer non-invasive medical treatment to surgical evacuation.

In the western, the combined regimen of mifepristone followed 36 – 48 hours later by the prostaglandin E1 analgoue misoprostol is generally used for the medical treatment of the first trimester abortion with high efficacy and good patient acceptability\(^{(8-10)}\). Medical abortion using the anti-progesterone mifepristone and prostaglandin analogue was approved in France, UK, and Sweden in 1988, 1991 and 1992, respectively. In the USA, mifepristone was approved for medical abortion in 2000\(^{(11)}\).

Misoprostol, a synthetic analogue of natural prostaglandin E1, was first marketed in the 1980s to prevent gastric or duodenal ulcer. Misoprostol has been used for long time, also it is inexpensive, easy to be kept at room temperature. Misoprostol has additional effect on uterine
contractility and cervical ripening, so World Health Organization (WHO) recommended misoprostol for obstetric and gynaecologic indications\(^{(12)}\).

In obstetric or gynecologic use, misoprostol can be administrated widely via vaginal as well as oral or sublingual routes. The pharmacokinetics of misoprostol showed that serum concentrations of vaginally administrated misoprostol were higher than those of orally administrated misoprostol\(^{(13)}\). However, the efficacy between vaginal route and oral or sublingual route was known to be equivalent and oral or sublingual route is much easier to be taken than vaginal route. Previous studies reported the effectiveness of vaginal misoprostol\(^{(14-23)}\).

Diagnosis of missed miscarriage is considered when we met one of the following criteria:

- Crown–rump length (CRL) of at least 7 mm and no heartbeat;
- Mean gestational sac diameter of at least 25 mm and no embryo;
- No embryo with heartbeat on a follow-up scan at least 2 weeks after an initial ultrasound scan that showed a gestational sac without a yolk sac;
- No embryo with heartbeat on a follow-up scan at least 11 days after an initial ultrasound scan that showed a gestational sac with a yolk sac\(^{(4)}\).

**Aim of the work:**

In this study, we tried to determine the outcome of medical treatment with vaginal misoprostol in the first trimester miscarriage, and the need for surgical abortion.

**MATERIALS AND METHODS**

Eighty cases with first trimester missed miscarriage, diagnosed either clinically by presentation of mild vaginal bleeding or during follow up by ultrasound, are included in our study.

The study population was consisted of patients who were 18 to 42 years old, primigravida to para 4 wheather vaginal delivery (V.D.) or cesarean section (C.S), diagnosed with miscarriage before 14 weeks of gestation in Department of Obstetrics and Gynaecology, Benha Teaching Hospital, from April 2016 to June 2017.

Those who wanted to avoid surgical intervention and waited until the next day after taking misoprostol as a medical treatment for termination of first trimester missed miscarriage, were enrolled in this study.

Complete history taking, complete physical examination and routine laboratory investigations included complete urine analysis complete blood count, blood sugar level and coagulation profile were done.

The corrected gestational sac was determined by measurement of the size of gestational sac or CRL at the point of diagnosis of miscarriage by ultrasound.

Patients not suitable for medical abortion with misoprostol were excluded, such as presence of considerable vaginal bleeding, suspected molar pregnancy, suspected ectopic pregnancy or contra-indication to prostaglandin.

Participants received 400 microgram (mcg) of misoprostol vaginal at the level of external cervical os as initial dose, and repeated the same dose 4 – 5 hours apart. At least 24 hours later after the first dose, patients were examined by ultrasound scan to verify whether gestational products were remained in the uterine cavity or not.
Successful medical abortion was defined as spontaneous expulsion of gestational products at least 24 hours later from the initial dose.

If gestational products were not expelled spontaneously, surgical evacuation was performed.

We defined the successful medical treatment group as patients with spontaneous expulsion of gestational products by vaginal misoprostol and the failed medical treatment group as those with remained gestational products despite medications whether incomplete abortion or no response to vaginal misoprostol or those with severe vaginal bleeding needed immediate surgical interference. We evaluated the side effects of misoprostol, such as fever chilling sense, nausea, vomiting abdominal pain or diarrhea.

The statistical analysis was performed using SPSS version 20.0 for windows (SPSS Inc., Chincago IL, USA). Comparison of the continuous variables was carried out using the Mann-Whitney U test, and proportions were compared using pear – son’s $X^2$ test. A probability value of $< 0.05$ was considered statistically significant.

**RESULTS**

Eighty cases with first trimester miscarriage diagnosed clinically by presentation of mild vaginal bleeding, or during follow up, where diagnosis was confirmed by ultrasonography.

All cases were hospitalized for trial of medical abortion. Sixty two patients (77.5%) had successful outcome until the next day, after taking vaginal misoprostol, where they were classified as the successful medical treatment group. The other eighteen patients (22.5%), underwent surgical evacuation, and were classified as the failed medical treatment group with statistically significant difference ($P < 0.05$) (Table 1).

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Number (n)</th>
<th>Percent (%)</th>
<th>P – value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Successful medical treatment group</td>
<td>62</td>
<td>77.5</td>
<td></td>
</tr>
<tr>
<td>Failed medical treatment group</td>
<td>18</td>
<td>22.5</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>80</td>
<td>100</td>
<td>$&lt; 0.05$</td>
</tr>
</tbody>
</table>

As regarding, the age, in the successful medical treatment group, the age in years ranged from 18 to 42 years with a median of (32) years, and ranged from 18 to 40 years with a median of (30.5) years in the failed medical treatment group, with no statistically significant difference ($P = 0.253$) (Table 2).

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Successful medical treatment group (n = 62)</th>
<th>Failed medical treatment group (n = 18)</th>
<th>P – value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yers)</td>
<td>32 (18 – 42)</td>
<td>30.5 (18 – 40)</td>
<td>0.253</td>
</tr>
<tr>
<td>Nulliparity</td>
<td>13 (20.96%)</td>
<td>4 (22.22%)</td>
<td>0.383</td>
</tr>
<tr>
<td>Para one</td>
<td>14 (22.58%)</td>
<td>4 (22.22%)</td>
<td>0.480</td>
</tr>
<tr>
<td>Para two</td>
<td>12 (19.35%)</td>
<td>4 (22.22%)</td>
<td>0.370</td>
</tr>
<tr>
<td>Para three</td>
<td>12 (19.35%)</td>
<td>3 (16.66%)</td>
<td>0.256</td>
</tr>
<tr>
<td>Para four</td>
<td>11 (17.74%)</td>
<td>3 (16.66%)</td>
<td>0.246</td>
</tr>
</tbody>
</table>
As regarding to parity, the successful medical treatment group were nulliparas 13 cases (20.96%), para one, 14 cases (22.58%), para two, 12 cases (19.35%), para three 12 cases (19.35%) and para four, 11 cases (17.74%) and the failed medical treatment group were nulliparas, 4 cases (22.22%), para one, 4 cases (22.22%), para two, 4 cases (22.22%), para three, 3 cases (16.66%) and para four, 3 cases (16.66%), with no statistically significant difference, as regarding the parity in both groups (Table 2).

As regarding the mode of delivery wether through vaginal delivery (V.D), or through cesarean section (C.S), the successful medical treatment group were nulliparas, 13 cases, para one, 14 cases (8 cases through V.D and 6 cases through C.S), para two, 12 cases, (6 cases through V.D and 6 cases through C.S), para three, 12 cases, (7 cases through V.D and 5 cases, through C.S), para four, 11 cases (6 cases through V.D and 5 cases through C.S) and the failed medical treatment group were nulliparas, 4 cases, para one, 4 cases (2 cases through V.D and 2 cases through C.S) para three, 3 cases (2 cases through V.D and one case through C.S) para four, 3 cases, 2 cases through V.D and one case through C.S).

With no statistically significant difference between the two groups as regarding the mode of previous delivery (Table 3).

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Successful group (no = 62)</th>
<th>Failed group (n = 18)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Number Percent</td>
<td>V.D</td>
<td>C.S</td>
</tr>
<tr>
<td>Nullipara</td>
<td>13 cases 22.96%</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Para one</td>
<td>14 cases 22.58%</td>
<td>8</td>
<td>6</td>
</tr>
<tr>
<td>para two</td>
<td>12 cases 19.35%</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>Para three</td>
<td>12 cases 19.25%</td>
<td>7</td>
<td>5</td>
</tr>
<tr>
<td>Para four</td>
<td>11 cases 17.74%</td>
<td>6</td>
<td>5</td>
</tr>
</tbody>
</table>

As regarding the failed medical treatment group, where surgical evacuation was done, they were, 8 cases (10%) had incomplete miscarriage, 5 cases (6.25%) due to severe bleeding, and 5 cases (6.25%), due to failed response to vaginal misoprostal, Table (4).

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Number of cases</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incomplete miscarriage</td>
<td>8</td>
<td>10%</td>
</tr>
<tr>
<td>Severe bleeding</td>
<td>5</td>
<td>6.25%</td>
</tr>
<tr>
<td>No response</td>
<td>5</td>
<td>6.25%</td>
</tr>
<tr>
<td>Total</td>
<td>18</td>
<td>22.5%</td>
</tr>
</tbody>
</table>

**DISCUSSION**

The principal findings of this study were following: 1) gestational products were spontaneously expelled in about two-thirds of patients with only vaginal misoprostol until the
Vaginal misoprostal in the first trimester miscarriage can be a proper option to the patients who have fear about surgery and anesthesia, and want to avoid any surgical intervention. Although we conducted surgical evacuation the next day for the remained gestational products in this study, it is also possible to observe more without surgical intervention. If the patients in the failed medical treatment group took additional misoprostol and waited a few more days, the rate of successful medical treatment would have increased.

A pharmacokinetics – related study addressed that the plasma concentrations of misoprostol was higher in vaginal insertion than in oral administration, but several serious complications were associated with vaginal misoprostol such as premature separation of placenta, postpartum hemorrhage, uterine rupture and amniotic fluid embolism in patients with fetal demise\(^{(24,25)}\). There was 5 cases of severe bleeding.

In spite of recent advances in surgical techniques and perioperative care, surgical curettage of the gravid uterus is a risk factor for intrauterine adhesions and abnormally invasive placenta in subsequent pregnancy\(^{(26,27)}\). Spontaneous expulsion of gestational products induced by misoprostol dose not hurt uterus.

According to the 2006 WHO frequently asked clinical questions about medical abortion, several factors should be taken into account when counseling a woman about her choice between medical and surgical abortion\(^{(28)}\). Besides of patients who want to avoid surgical intervention and anesthesia, there are several favorable conditions for medical abortion as follows: 1) very early gestation; up to 49 days of gestation, medical abortion is considered to be more effective than surgical abortion; 2) severe obesity body mass index (BMI), greater than 30); 3) uterine malformations or a fibroid uterus, or previous cervical surgery. Maternal severe obesity or uterine malformation make surgical intervention difficult\(^{(28)}\).

Although not included in this study, there was a case transferred from local clinic to our hospital because of failed surgical treatment of miscarriage. She had a bicornuate uterus, and gestational products were located in the right uterus. We tried to evacuate the gestational products surgically, but eventually failed to access to the right uterus with gestational products. She took 400 mcg of misoprostol and repeated the same dose 4 hours later. After 14 hours later since the initial pill, the gestational products came down to the external os of cervix, on examination, we easily removed the gestational products.

There are several strengths and limits of this study. Despite, the limitations of our study are attributable to the inherent weakness of a retrospective study and small sample size. If further prospective studies with a large population identify some contributing factors associated with successful medical treatment, it will be helpful in the counseling of patients.

**CONCLUSION**

In conclusion, medical treatment with vaginal misoprostol (MS) can be a proper option for the first trimester miscarriage without any serious complications, especially for the patients who want to avoid surgical procedure. We can reduce the unnecessary sedation or surgical intervention in the patients with the first trimester miscarriage.
ACKNOWLEDGEMENTS
This research was supported by General Organization of Teaching Hospitals and Institutes (GOTHI), Ministry of health.

CONFLICT OF INTEREST
No potential conflict of interest relevant to this article was reported.

References

National Collaborating Centre for Women’s and Child-dren’s Health (GB); National Institute for Health and Clinical Excellence (GB); Royal College of Obstetricians and Gynaecologists (GB). Ectopic pregnancy and miscarriage: diagnosis and initial management in early pregnancy of ectopic pregnancy and miscarriage. London (GB): Royal College of Obstetricians and Gynaecologists; 2012.


Olivier A, Overton C. Diagnosis and management of miscarriage. Practitioner 2014; 258 : 25 – 8, 23.


